SCHEMBL5592903

SCHEMBL5592903

COc1cc(C)c(Cl)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
EPHB4 P54760 2/20 0.46
ALDH1A1 P00352 4/20 0.43
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 1/20 0.43
ERBB4 Q15303 1/20 0.43
CHEK1 O14757 1/20 0.42
IKBKB O14920 1/20 0.42
AURKA O14965 1/20 0.42
DCLK1 O15075 1/20 0.42
RPS6KA5 O75582 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
RET P07949 1/20 0.42
PHKG2 P15735 1/20 0.42
CDK2 P24941 1/20 0.42
FLT4 P35916 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
CLK2 P49760 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5611827 0.90 EPHB4 (0.45) MAPTEPHB4ALDH1A1LMNASMN1; SMN2
SCHEMBL5593101 0.90 MAPT (0.43) MAPTEPHB4ALDH1A1LMNASMN1; SMN2
SCHEMBL5586117 0.88 MAPT (0.42) MAPTEPHB4LMNAERBB4CHEK1
SCHEMBL5592620 0.88 EPHB4 (0.47) MAPTEPHB4ALDH1A1LMNASMN1; SMN2
SCHEMBL5592628 0.86 ERBB4 (0.43) MAPTEPHB4ALDH1A1LMNASMN1; SMN2
SCHEMBL5592697 0.86 EPHB4 (0.47) MAPTEPHB4ALDH1A1LMNAERBB4
SCHEMBL5602071 0.85 HTR2C (0.54) MAPTEPHB4ALDH1A1LMNASMN1; SMN2
SCHEMBL12028947 0.85 THRA (0.44) MAPTEPHB4ALDH1A1LMNASMN1; SMN2
SCHEMBL5585843 0.84 EPHB4 (0.52) MAPTEPHB4ALDH1A1LMNASMN1; SMN2
SCHEMBL5592573 0.84 MEN1 (0.49) MAPTEPHB4ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP claimed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US claimed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP disclosed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US disclosed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity UCK2, CHUK, AXL MAPT 2782/4885EPHB4 3357/4885ALDH1A1 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.